## Akira Matsumori

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7047290/publications.pdf

Version: 2024-02-01

57758 54911 7,598 129 44 84 citations h-index g-index papers 130 130 130 6636 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Novel Biomarkers of Inflammation for the Management of Diabetes: Immunoglobulin-Free Light Chains. Biomedicines, 2022, 10, 666.	3.2	8
2	Myocarditis and Pericarditis., 2021,,.		1
3	Diagnosis and treatment of HCV heart diseases. Expert Review of Cardiovascular Therapy, 2021, 19, 493-499.	1.5	10
4	Immunoglobulin Free Light Chains as Inflammatory Biomarkers of Atrial Fibrillation. Circulation: Arrhythmia and Electrophysiology, 2020, 13, e009017.	4.8	9
5	Myocardial involvement in coronavirus disease 19. Herz, 2020, 45, 719-725.	1.1	15
6	Immunoglobulin free light chains: an inflammatory biomarker of diabetes. Inflammation Research, 2020, 69, 715-718.	4.0	14
7	Immunoglobulin free light chains as an inflammatory biomarker of heart failure with myocarditis. Clinical Immunology, 2020, 217, 108455.	3.2	11
8	Inhibitory effects of Pycnogenol® on hepatitis C virus replication. Antiviral Research, 2015, 113, 93-102.	4.1	19
9	The Global Burden of Myocarditis: Part 1: A Systematic Literature Review for the Global Burden of Diseases, Injuries, and Risk Factors 2010 Study. Global Heart, 2014, 9, 121.	2.3	110
10	Calcium channel blockers and modulation of innate immunity. Current Opinion in Infectious Diseases, 2011, 24, 254-258.	3.1	32
11	Calcium Channel Blockers Differentially Modulate Cytokine Production by Peripheral Blood Mononuclear Cells. Circulation Journal, 2010, 74, 567-571.	1.6	47
12	Role of substance P in viral myocarditis in mice. Heart and Vessels, 2010, 25, 348-352.	1.2	5
13	Effects of Free Immunoglobulin Light Chains on Viral Myocarditis. Circulation Research, 2010, 106, 1533-1540.	4.5	34
14	Leukocytes are the major target of hepatitis C virus infection: Possible mechanism of multiorgan involvement including the heart. CVD Prevention and Control, 2010, 5, 51.	0.7	9
15	Antiâ€inflammatory effects of eplerenone on viral myocarditis. European Journal of Heart Failure, 2009, 11, 349-353.	7.1	47
16	Gelsolin and Cardiac Myocyte Apoptosis. Circulation Research, 2009, 104, 829-831.	4.5	14
17	Nifedipine inhibits the activation of inflammatory and immune reactions in viral myocarditis. Life Sciences, 2009, 85, 235-240.	4.3	12
18	Global alert and response network for hepatitis C virus-derived heart diseases: A call to action. CVD Prevention and Control, 2009, 4, 109.	0.7	8

#	Article	IF	CITATIONS
19	Mast Cells Play a Critical Role in the Pathogenesis of Viral Myocarditis. Circulation, 2008, 118, 363-372.	1.6	58
20	Prognosis and Prognostic Factors in Patients With Idiopathic Dilated Cardiomyopathy in Japan Results From a Nationwide Study. Circulation Journal, 2008, 72, 343-348.	1.6	22
21	Prognosis and prognostic factors in patients with hypertrophic cardiomyopathy in Japan: results from a nationwide study. Heart, 2007, 93, 711-715.	2.9	28
22	French Maritime Pine Bark Extract Inhibits Viral Replication and Prevents Development of Viral Myocarditis. Journal of Cardiac Failure, 2007, 13, 785-791.	1.7	17
23	Treatment Options in Myocarditis. Herz, 2007, 32, 452-456.	1.1	14
24	Myocarditis and Heart Failure Associated With Hepatitis C Virus Infection. Journal of Cardiac Failure, 2006, 12, 293-298.	1.7	102
25	Histone Acetyltransferase Activity of p300 Is Required for the Promotion of Left Ventricular Remodeling After Myocardial Infarction in Adult Mice In Vivo. Circulation, 2006, 113, 679-690.	1.6	130
26	Emerging treatments for viral myocarditis. Future Cardiology, 2005, 1, 683-692.	1.2	1
27	Hepatitis C Virus Infection and Cardiomyopathies. Circulation Research, 2005, 96, 144-147.	4.5	90
28	Commentary. Evidence-based Cardiovascular Medicine, 2005, 9, 269-270.	0.0	0
29	Suppression of cytokines and nitric oxide production, and protection against lethal endotoxemia and viral myocarditis by a new NF-ήB inhibitor. European Journal of Heart Failure, 2004, 6, 137-144.	7.1	39
30	REDUCED HIGH SERUM HEPATOCYTE GROWTH FACTOR LEVELS AFTER SUCCESSFUL CARDIOVERSION IN PATIENTS WITH ATRIAL FIBRILLATION. Clinical and Experimental Pharmacology and Physiology, 2004, 31, 145-151.	1.9	11
31	Roles of Hepatocyte Growth Factor and Mast Cells in Thrombosis and Angiogenesis. Cardiovascular Drugs and Therapy, 2004, 18, 321-326.	2.6	10
32	Anti-inflammatory therapy for heart failure. Current Opinion in Pharmacology, 2004, 4, 171-176.	3.5	23
33	Hepatocyte Growth Factor and Cardiovascular Thrombosis in Patients Admitted to the Intensive Care Unit. Circulation Journal, 2004, 68, 645-649.	1.6	22
34	Hepatitis C virus-associated tubulointerstitial injury. American Journal of Kidney Diseases, 2003, 41, 767-775.	1.9	71
35	Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice. Nature Medicine, 2003, 9, 1477-1483.	30.7	606
36	Attenuation of virus-induced myocardial injury by inhibition of the angiotensin II type 1 receptor signal and decreased nuclear factor-kappa B activation in knockout mice. Journal of the American College of Cardiology, 2003, 42, 2000-2006.	2.8	36

3

#	Article	IF	Citations
37	Efficacy and safety of oral candesartan cilexetil in patients with congestive heart failure. European Journal of Heart Failure, 2003, 5, 669-677.	7.1	66
38	Gene Expression of Cardiac Mast Cell Chymase and Tryptase in a Murine Model of Heart Failure Caused by Viral Myocarditis. Circulation Journal, 2003, 67, 881-884.	1.6	45
39	Cardiomyopathies and Heart Failure. Developments in Cardiovascular Medicine, 2003, , 1-15.	0.1	3
40	Hepatitis Cvirus and Cardiomyopathy. Developments in Cardiovascular Medicine, 2003, , 325-339.	0.1	2
41	Genes of the Major Histocompability Complex Class II Influence the Phenotype of Cardiomyopathies Associated With Hepatitis C Virus Infection. Developments in Cardiovascular Medicine, 2003, , 515-521.	0.1	4
42	Thrombosis Increases Circulatory Hepatocyte Growth Factor by Degranulation of Mast Cells. Circulation, 2002, 106, 3133-3138.	1.6	21
43	Evidence for a Role of Mast Cells in the Evolution to Congestive Heart Failure. Journal of Experimental Medicine, 2002, 195, 375-381.	8.5	224
44	Circulating Hepatocyte Growth Factor as a Diagnostic Marker of Thrombus Formation in Patients With Cerebral Infarction. Circulation Journal, 2002, 66, 216-218.	1.6	30
45	Epidemiologic and Clinical Characteristics of Cardiomyopathies in Japan. Results From Nationwide Surveys Circulation Journal, 2002, 66, 323-336.	1.6	76
46	AMIODARONE INHIBITS INTERLEUKIN 6 PRODUCTION AND ATTENUATES MYOCARDIAL INJURY INDUCED BY VIRAL MYOCARDITIS IN MICE. Cytokine, 2002, 17, 197-202.	3.2	23
47	Left ventricular pressure-volume relationship in a murine model of congestive heart failure due to acute viral myocarditis. Journal of the American College of Cardiology, 2002, 40, 1506-1514.	2.8	36
48	Heparin accelerates liver regeneration following portal branch ligation in normal and cirrhotic rats with increased plasma hepatocyte growth factor levels. Journal of Hepatology, 2002, 37, 87-92.	3.7	14
49	Endothelin Antagonism with Bosentan: Current Status and Future Perspectives. Cardiovascular Drug Reviews, 2002, 20, 1-18.	4.1	11
50	Therapeutic effects of FTY720, a new immunosuppressive agent, in a murine model of acute viral myocarditis. Journal of the American College of Cardiology, 2001, 37, 1713-1718.	2.8	30
51	Neutralization of interleukin- $1\hat{l}^2$ in the acute phase of myocardial infarction promotes the progression of left ventricular remodeling. Journal of the American College of Cardiology, 2001, 38, 1546-1553.	2.8	134
52	Role of Cytokines in Autoimmune Myocarditis and Cardiomyopathy. Autoimmunity, 2001, 34, 165-168.	2.6	21
53	Cytokine Gene Therapy for Myocarditis by In Vivo Electroporation. Human Gene Therapy, 2001, 12, 1289-1297.	2.7	65
54	Hepatitis C Virus and Cardiomyopathy. Internal Medicine, 2001, 40, 78-79.	0.7	12

#	Article	IF	Citations
55	Clinical Practice of Hepatitis: Myocardial Diseases, Nephritis, and Vasculitis Associated with Hepatitis Virus Internal Medicine, 2001, 40, 182-184.	0.7	11
56	The role of inflammatory mediators in the failing heart: immunomodulation of cytokines in experimental models of heart failure. , 2001, 6, 129-136.		25
57	Serial evaluation of fatty acid metabolism in rats with myocardial infarction by pinhole SPECT. Journal of Nuclear Cardiology, 2001, 8, 472-481.	2.1	16
58	Immunomodulation of Cytokines in Experimental Models of Heart Failure. Developments in Cardiovascular Medicine, 2001, , 69-76.	0.1	0
59	Interferon Treatment for Dilated Cardiomyopathy and Striated Myopathy Associated With Hepatitis C Virus Infection Based on Serial Measurements of Serum Concentrations of Cardiac Troponin T. Japanese Circulation Journal, 2000, 64, 321-324.	1.0	30
60	Hypertrophic Cardiomyopathy as a Manifestation of Cardiac Sarcoidosis. Japanese Circulation Journal, 2000, 64, 679-683.	1.0	42
61	Circulating Hepatocyte Growth Factor as a Marker of Thrombus Formation in Unstable Angina Pectoris. Japanese Circulation Journal, 2000, 64, 805-807.	1.0	10
62	Measurement of Serum Concentrations of Cardiac Troponin T in Patients with Hypereosinophilic Syndrome. A Sensitive Non-invasive Marker of Cardiac Disorder Internal Medicine, 2000, 39, 350.	0.7	28
63	Roles and Relationship of Macrophages and Monocyte Chemotactic and Activating Factor/Monocyte Chemoattractant Protein-1 in the Ischemic and Reperfused Rat Heart. Laboratory Investigation, 2000, 80, 1127-1136.	3.7	86
64	Hepatitis C Virus from the Hearts of Patients with Myocarditis and Cardiomyopathy. Laboratory Investigation, 2000, 80, 1137-1142.	3.7	100
65	Hepatitis C Virus and Cardiomyopathy. Herz, 2000, 25, 249-254.	1.1	18
66	Characterization of the human nebulette gene: a polymorphism in an actin-binding motif is associated with nonfamilial idiopathic dilated cardiomyopathy. Human Genetics, 2000, 107, 440-451.	3.8	55
67	AMLODIPINE INHIBITS THE PRODUCTION OF CYTOKINES INDUCED BY OUABAIN. Cytokine, 2000, 12, 294-297.	3.2	30
68	Pimobendan inhibits the activation of transcription factor NF-κB. Life Sciences, 2000, 67, 2513-2519.	4.3	30
69	Nifedipine inhibits activation of transcription factor NF-κB. Life Sciences, 2000, 67, 2655-2661.	4.3	44
70	Cytokines and Heart Failure: Pathophysiological Roles and Therapeutic Implications. , 2000, , 35-45.		0
71	Mast Cells Cause Apoptosis of Cardiomyocytes and Proliferation of Other Intramyocardial Cells In Vitro. Circulation, 1999, 100, 1443-1449.	1.6	109
72	Contribution of Endothelin-1 to Myocardial Injury in a Murine Model of Myocarditis. Circulation, 1999, 100, 1823-1829.	1.6	40

#	Article	IF	Citations
73	Anti–Monocyte Chemoattractant Protein-1/Monocyte Chemotactic and Activating Factor Antibody Inhibits Neointimal Hyperplasia in Injured Rat Carotid Arteries. Circulation Research, 1999, 84, 306-314.	4.5	222
74	FTY720, a New Immunosuppressant, Promotes Long-Term Graft Survival and Inhibits the Progression of Graft Coronary Artery Disease in a Murine Model of Cardiac Transplantation. Circulation, 1999, 100, 1322-1329.	1.6	83
75	Treatment of Experimental Viral Myocarditis With Interleukin-10. Circulation, 1999, 100, 1102-1108.	1.6	130
76	Transition from Compensated to Decompensated Cardiac Hypertrophy. Heart Failure Reviews, 1999, 4, 379-388.	3.9	1
77	Effects of pranidipine, a calcium channel antagonist, in an avian model of heart failure. Cardiovascular Drugs and Therapy, 1999, 13, 455-463.	2.6	8
78	Serial circulating concentrations of câ€reactive protein, interleukin (il)â€4, and ilâ€6 in patients with acute left heart decompensation. Clinical Cardiology, 1999, 22, 811-813.	1.8	136
79	Pimobendan inhibits the production of proinflammatory cytokines and gene expression of inducible nitric oxide synthase in a murine model of viral myocarditis. Journal of the American College of Cardiology, 1999, 33, 1400-1407.	2.8	81
80	Hepatocyte Growth Factor Is a Major Mediator in Heparin-Induced Angiogenesis. Biochemical and Biophysical Research Communications, 1999, 255, 80-87.	2.1	31
81	A Patient With Hypertrophic Cardiomyopathy Accompanied by Right Ventricular Dilation of Unknown Cause. Japanese Circulation Journal, 1999, 63, 137-140.	1.0	0
82	Apical Hypertrophic Cardiomyopathy and Hepatitis C Virus Infection. Japanese Circulation Journal, 1999, 63, 433-438.	1.0	30
83	High Doses of Digitalis Increase the Myocardial Production of Proinflammatory Cytokines and Worsen Myocardial Injury in Viral Myocarditis. Japanese Circulation Journal, 1999, 63, 934-940.	1.0	68
84	Cytokine Gene Expression During the Development of Graft Coronary Artery Disease in Mice. Japanese Circulation Journal, 1999, 63, 775-782.	1.0	12
85	Protective effects of Mu-Fang-Ji-Tang against myocardial injury in a murine model of congestive heart failure induced by viral myocarditis. Life Sciences, 1998, 62, 1139-1146.	4.3	4
86	Denopamine, a $\hat{l}^21$ -adrenergic agonist, prolongs survival in a murine model of congestive heart failure induced by viral myocarditis: suppression of tumor necrosis factor- $\hat{l}\pm$ production in the heart. Journal of the American College of Cardiology, 1998, 32, 808-815.	2.8	23
87	Immediate Increase in Circulating Hepatocyte Growth Factor/Scatter Factor by Heparin. Journal of Molecular and Cellular Cardiology, 1998, 30, 2145-2149.	1.9	37
88	Cytokine Gene Expression After Myocardial Infarction in Rat Hearts. Circulation, 1998, 98, 149-156.	1.6	407
89	Cyclic Stretch Upregulates Production of Interleukin-8 and Monocyte Chemotactic and Activating Factor/Monocyte Chemoattractant Protein-1 in Human Endothelial Cells. Arteriosclerosis, Thrombosis, and Vascular Biology, 1998, 18, 894-901.	2.4	143
90	Circulating Hepatocyte Growth Factor as an Early Marker of Arterial Thrombus Formation. Japanese Circulation Journal, 1998, 62, 311-313.	1.0	20

#	Article	IF	Citations
91	Hepatitis C Virus Infection and Heart Diseases. Japanese Circulation Journal, 1998, 62, 389-391.	1.0	58
92	Hepatitis C Virus Infection and Hypertrophic Cardiomyopathy. Annals of Internal Medicine, 1998, 129, 749.	3.9	24
93	Molecular and Immune Mechanisms in the Pathogenesis of Cardiomyopathy. Japanese Circulation Journal, 1997, 61, 275-291.	1.0	80
94	Plasma Levels of the Monocyte Chemotactic and Activating Factor/Monocyte Chemoattractant Protein-1 are Elevated in Patients with Acute Myocardial Infarction. Journal of Molecular and Cellular Cardiology, 1997, 29, 419-423.	1.9	140
95	Protective Role of Interleukin-12 in Viral Myocarditis. Journal of Molecular and Cellular Cardiology, 1997, 29, 2327-2334.	1.9	34
96	The use of cytokine inhibitors. International Journal of Cardiology, 1997, 62, S3-S12.	1.7	22
97	Calcium channel blocker-induced protection against cardiovascular damage. International Journal of Cardiology, 1997, 62, S39-S46.	1.7	19
98	Beneficial Effects of Amlodipine in a Murine Model of Congestive Heart Failure Induced by Viral Myocarditis. Circulation, 1997, 95, 245-251.	1.6	74
99	Enhanced Expression of Hepatocyte Growth Factor/c-Met by Myocardial Ischemia and Reperfusion in a Rat Model. Circulation, 1997, 95, 2552-2558.	1.6	182
100	Amiodarone Inhibits Production of Tumor Necrosis Factor- $\hat{l}_{\pm}$ by Human Mononuclear Cells. Circulation, 1997, 96, 1386-1389.	1.6	82
101	Modulation of Cytokine Production and Protection Against Lethal Endotoxemia by the Cardiac Glycoside Ouabain. Circulation, 1997, 96, 1501-1506.	1.6	79
102	Increased Expression of Interleukin- $1\hat{l}^2$ and Monocyte Chemotactic and Activating Factor/Monocyte Chemoattractant Protein-1 in the Hypertrophied and Failing Heart With Pressure Overload. Circulation Research, 1997, 81, 664-671.	4.5	158
103	Inotropic agents differentially inhibit the induction of nitric oxide synthase by endotoxin in cultured macrophages. Life Sciences, 1996, 59, PL121-PL125.	4.3	18
104	Differential Modulation of Cytokine Production by Drugs: Implications for Therapy in Heart Failure. Journal of Molecular and Cellular Cardiology, 1996, 28, 2491-2499.	1.9	56
105	Increased Circulating Hepatocyte Growth Factor in the Early Stage of Acute Myocardial Infarction. Biochemical and Biophysical Research Communications, 1996, 221, 391-395.	2.1	93
106	Detection of Hepatitis C Virus RNA from the Heart of Patients with Hypertrophic Cardiomyopathy. Biochemical and Biophysical Research Communications, 1996, 222, 678-682.	2.1	74
107	Cytokines in myocarditis and cardiomyopathies. Current Opinion in Cardiology, 1996, 11, 302-309.	1.8	57
108	Role of Cytokines in the Syndrome of Heart Failure Internal Medicine, 1996, 35, 60-63.	0.7	6

#	Article	IF	Citations
109	Comparative study of 201Tl-scintigraphic image and myocardial pathologic findings in patients with dilated cardiomyopathy. Annals of Nuclear Medicine, 1996, 10, 307-314.	2.2	24
110	Elevated circulating levels of tumor necrosis factor in patients with mitral valve disease and ventricular septum defect. Heart and Vessels, 1996, 11, 218-220.	1.2	2
111	Immunomodulatory therapy and survival with cardiac disease. Heart Failure Reviews, 1996, 1, 221-227.	3.9	0
112	Angiotensin II Receptor Antagonist TCV-116 Reduces Graft Coronary Artery Disease and Preserves Graft Status in a Murine Model. Circulation, 1996, 93, 333-339.	1.6	60
113	Persistent Expression of Cytokine in the Chronic Stage of Viral Myocarditis in Mice. Circulation, 1996, 94, 2930-2937.	1.6	140
114	Mutations in the Genes for Cardiac Troponin T and α-Tropomyosin in Hypertrophic Cardiomyopathy. New England Journal of Medicine, 1995, 332, 1058-1065.	27.0	887
115	Inotropic agent vesnarinone inhibits cytokine production and E-selectin expression in human umbilical vein endothelial cells. Journal of Molecular and Cellular Cardiology, 1995, 27, 2265-2273.	1.9	33
116	Dilated Cardiomyopathy Associated With Hepatitis C Virus Infection. Circulation, 1995, 92, 2519-2525.	1.6	167
117	Vesnarinone prolongs survival and reduces lethality in a murine model of lethal endotoxemia. Life Sciences, 1994, 55, 1735-1741.	4.3	16
118	Inhibition of cytokine production by a new inotropic agent, vesnarinone, in human lymphocytes, T cell line, and monocytic cell line. Life Sciences, 1994, 54, PL11-PL16.	4.3	36
119	Autoantibodies Against Vimentin in a Murine Model of Myocarditis. Autoimmunity, 1994, 18, 145-148.	2.6	18
120	Successive infection of coxsackievirus B3 and encephalomyocarditis virus: An animal model of chronic myocarditis. Journal of Pathology, 1992, 167, 341-347.	4.5	9
121	Pathogenesis and preventive and therapeutic trials in an animal model of dilated cardiomyopathy induced by a virus Japanese Circulation Journal, 1987, 51, 661-664.	1.0	14
122	Prevention of viral myocarditis with recombinant human leukocyte interferon $\hat{l}_{\pm}$ A/D in a murine model. Journal of the American College of Cardiology, 1987, 9, 1320-1325.	2.8	61
123	Effects of prednisolone on acute viral myocarditis in mice. Journal of the American College of Cardiology, 1986, 7, 868-872.	2.8	124
124	Mural thrombus in experimental viral myocarditis in mice: relation between thrombosis and congestive heart failure. Cardiovascular Research, 1986, 20, 665-671.	3.8	23
125	Right ventricular aneurysms complicating encephalomyocarditis virus myocarditis in mice Japanese Circulation Journal, 1983, 47, 1322-1324.	1.0	10
126	Encephalomyocarditis virus myocarditis in inbred strains of mice. Chronic stage Japanese Circulation Journal, 1982, 46, 1192-1196.	1.0	22

#	Article	IF	CITATIONS
127	Encephalomyocarditis (EMC) virus myocarditis in DBA/2 mice. I. Acute stage Japanese Circulation Journal, 1981, 45, 1403-1408.	1.0	9
128	Coxsackie virus B3 perimyocarditis in BALB/c mice: Experimental model of chronic perimyocarditis in the right ventricle. Journal of Pathology, 1980, 131, 97-106.	4.5	74
129	Immunoglobulin Free Light Chains: A Biomarker of Diabetes. SSRN Electronic Journal, 0, , .	0.4	1